|
|
|||||||||
|
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail. Compendium of Psittacosis (Chlamydiosis) Control, 1997Summary Infection with Chlamydia psittaci, often referred to as avian chlamydiosis (AC), is an important cause of systemic illness in companion birds (i.e., birds kept by humans as pets) and poultry. Infection can be transmitted from infected birds to humans. In humans, infection caused by C. psittaci is referred to as psittacosis, which can result in fatal pneumonia. This compendium provides information on AC (also known as psittacosis, ornithosis, and parrot fever) and psittacosis (also known as parrot disease, parrot fever, and chlamydiosis) to public health officials, veterinarians, physicians, the companion-bird industry, and others concerned with control of the disease and protection of public health. These recommendations provide effective, standardized disease control procedures for AC in companion birds and will be reviewed and revised as necessary. INTRODUCTION In this report, psittacosis (also known as parrot disease, parrot fever, and chlamydiosis) refers to any infection or disease in humans caused by Chlamydia psittaci. Avian chlamydiosis (AC) refers to any infection with or disease caused by C. psittaci in birds. This compendium provides information on AC and psittacosis to public health officials, veterinarians, physicians, the companion-bird industry, and others concerned with control of the disease and protection of public health. These recommendations provide effective, standardized disease control procedures for AC in companion birds and will be reviewed and revised as necessary. PART I. C. psittaci INFECTION AMONG BIRDS (AVIAN CHLAMYDIOSIS) AC is a zoonotic disease caused by the bacterium C. psittaci. This bacterium has been isolated from 129 avian species and is most commonly identified in psittacine birds (e.g., parakeets, parrots, macaws, and cockatiels). Among caged, nonpsittacine birds, infection with C. psittaci occurs most frequently in pigeons, doves, and mynah birds. The incidence of infection in canaries and finches is believed to be lower than in other psittacine birds. The time between exposure to C. psittaci and the onset of illness in caged birds ranges from 3 days to several weeks. However, latent infections are common in birds, and active disease may appear years after exposure. Shipping, crowding, chilling, breeding, and other stress factors may activate shedding of the infectious agent among birds with latent infection. Birds may appear healthy but may be carriers of C. psittaci and may shed the organism intermittently. When shedding occurs, the organism is excreted in the feces and nasal discharges of infected birds, is resistant to drying, and can remain infective for several months. Clinical Signs of Chlamydial Infection in Birds Chlamydial infection in birds may be asymptomatic, or it may become an acute, a subacute, or a chronic clinical disease. Signs depend on the species of bird, virulence of the strain, stresses on the bird, and route of exposure. Birds with symptomatic AC typically have manifestations (e.g., lethargy, anorexia, and ruffled feathers) consistent with those of other systemic illnesses. Other signs associated with AC include serous or mucopurulent ocular or nasal discharge, diarrhea, and excretion of green to yellow-green urates. Anorectic birds may produce sparse, dark-green droppings. Birds may die soon after onset of illness or, as the disease progresses, may become emaciated and dehydrated before death. Mortality depends on stress factors, virulence of strain, species and age of bird, and extent of treatment or prophylaxis. Case Classification for Avian Chlamydiosis A confirmed case of AC is defined as infection by C. psittaci based on at least one of the following confirmatory laboratory results: a) isolation of C. psittaci from a clinical specimen, b) identification of Chlamydia antigen by immunofluorescence (fluorescent antibody {FA}) or enzyme-linked immunosorbent assay (ELISA) of the bird's tissues, c) a greater than fourfold change in serologic titer in two specimens from the bird obtained at least 2 weeks apart and assayed in parallel at the same laboratory, or d) identification of Chlamydia organisms within macrophages in smears stained with Gimenez or Machiavelo stain or sections of the bird's tissues. A probable case of AC is defined as infection by C. psittaci in a bird that has clinical illness compatible with AC and at least one of the following confirmatory laboratory results: a) one high serologic titer in one or more specimens obtained after the onset of signs or b) the presence of C. psittaci antigen (identified by ELISA or FA) in feces, a cloacal swab, or respiratory or ocular exudates. A suspected case of avian chlamydiosis is defined as a) clinical illness compatible with AC that is epidemiologically linked to another case in a human or bird but that is not laboratory confirmed; b) an asymptomatic infection in a bird for which laboratory results are equivocal (e.g., a single serologic titer of greater than or equal to 1:64); c) illness in a bird that has positive results for infection based on a nonstandardized test or a new investigational test; or d) a clinical illness compatible with chlamydiosis that is responsive to appropriate therapy. Several diagnostic methods are available for identifying AC in birds (Appendix A). General Recommendations for Treatment of Infected Birds All birds that have confirmed or probable AC should be placed in isolation and treated, preferably under the supervision of a veterinarian. Birds that have suspected cases or birds that have been exposed to AC should be isolated and retested or treated. Because treated birds can be reinfected by C. psittaci after treatment, such birds should be isolated from untreated birds or other potential sources of infection. To prevent reinfection from environmental sources, aviaries should be thoroughly cleaned and sanitized. No vaccine against chlamydiosis in birds is currently available. The following general recommendations should be followed by bird owners and dealers in treating birds that have confirmed, probable, or suspected cases of AC:
Recommended Control Measures The following control measures are recommended for veterinarians, physicians, and the companion-bird industry to prevent the transmission of C. psittaci infection to persons or other birds.
Responsibilities of Veterinarians Veterinarians should be aware that AC is not a rare disease in pet birds. The disease should be considered in any lethargic bird that has nonspecific signs of illness, especially if the bird was recently purchased. If AC is suspected, appropriate laboratory specimens should be submitted to a veterinary diagnostic laboratory to confirm the diagnosis. Both laboratories and attending veterinarians should follow local and state regulations or guidelines regarding the reporting of cases. Veterinarians should work closely with authorities who conduct investigations in their jurisdictions. When appropriate, veterinarians should inform their clients that infected birds should be isolated and treated. In addition, clients should be informed of a) the public health hazard posed by AC, b) appropriate precautions that should be taken to avoid the risk for transmission to persons and other companion birds, and c) the need to seek medical attention if persons exposed to the bird develop influenza-like symptoms or other respiratory illness. Quarantine The appropriate state animal and/or public health authorities may issue a quarantine for all affected and susceptible birds on a premises where infection has been identified. The purpose of imposing a quarantine is not to discourage disease reporting but to prevent further disease transmission (1). Because of the severe economic impact of quarantines, reasonable economic options should be made available to the owners and operators of pet stores. With the approval of state authorities, the owner of quarantined birds may choose one of two options: a) remove the birds from the premises and treat them in a separate quarantine area or b) euthanize the birds. After completion of the treatment or removal of the birds, a quarantine may be lifted when the infected premises are thoroughly cleaned and disinfected. The area can then be restocked with birds. Importation of Birds and Import Regulations The Veterinary Services of the Animal and Plant Health Inspection Service, U.S. Department of Agriculture (USDA), regulates the importation of pet birds to ensure that exotic poultry diseases are not introduced into the United States. These regulations are set forth in the Code of Federal Regulations (CFR), Title 9, Chapter 1 (1). Because of the possibility of smuggled pet birds, these import measures do not guarantee that avian chlamydiosis cannot enter the United States. In general, current USDA regulations regarding the importation of birds require --
PART II. C. psittaci INFECTION AMONG HUMANS (PSITTACOSIS) Because several diseases affecting humans can be caused by other species of Chlamydia, the disease resulting from the infection of humans with C. psittaci is frequently referred to as psittacosis. Most C. psittaci infections in humans result from exposure to psittacine birds. During 1985-1995, a total of 1,132 cases of psittacosis in humans was reported to CDC (2). Because the diagnosis of psittacosis can be difficult, these 1,132 cases probably represent an underestimation of the actual number of cases. During the 1980s, public health surveillance indicated that exposure to caged pet birds accounted for 70% of the psittacosis cases for which the source of infection was known; of these, owners of companion birds or bird fanciers were the largest group of affected persons (43%). Pet-shop employees accounted for an additional 10% of cases. Other persons at risk include pigeon fanciers and persons whose occupation places them at risk of exposure (e.g., employees in poultry-slaughtering/processing plants, veterinarians, veterinary technicians, laboratory workers, workers in avian quarantine stations, farmers, and zoo workers). Because human infection can result from transient exposure to infected birds or their contaminated droppings, persons with no identified avocational or occupational risk may become infected. Clinical Signs Human infection with C. psittaci usually occurs through the inhalation of the organism aerosolized from urine, respiratory secretions, or dried feces of infected birds. Other sources of exposure can include bird bites, mouth-to-beak contact, and handling the plumage and tissues of infected birds. Transient exposures may be adequate to induce infection. The incubation period is 5-14 days, and the severity of disease resulting from infection ranges from inapparent to severe systemic disease accompanied by pneumonia. Cases of symptomatic infection typically are characterized by abrupt onset of fever, chills, headache, malaise, and myalgia. A nonproductive cough usually develops, and a pulse-temperature dissociation sometimes occurs. Auscultatory findings may underestimate the extent of pulmonary involvement. Radiographic findings may include lobar or interstitial infiltrates. The differential diagnosis of psittacosis-related pneumonia may include infection by Coxiella burnetii, Mycoplasma pneumoniae spp., Chlamydia pneumoniae, Legionella spp., and viruses (e.g., influenza). Psittacosis may result in endocarditis, myocarditis, hepatitis, arthritis, keratoconjunctivitis, and encephalitis. Death occurs in less than 1% of properly treated patients. Case Definition A patient is considered to have a confirmed case of psittacosis if a) C. psittaci is cultured from clinical specimens or b) clinical illness is compatible with chlamydiosis and the antibody titer is increased by greater than fourfold (i.e., to greater than or equal to 32) as demonstrated by a complement-fixation (CF) or microimmunofluorescence (MIF) test for C. psittaci by either paired sera obtained at least 2 weeks apart or detection of IgM antibody (i.e., greater than or equal to 16) by MIF against C. psittaci. A patient is considered to have a probable case of psittacosis if there is a) a clinically compatible illness that is epidemiologically linked to a confirmed case or b) a single antibody titer greater than or equal to 32 by MIF or CF is present in at least one serum specimen obtained after onset of symptoms. These case definitions were established by CDC and the Council of State and Territorial Epidemiologists for epidemiologic purposes (3). They should not be used as sole criteria for establishing clinical diagnoses. Diagnosis Diagnosis almost always is established by using serologic methods in which paired sera are tested for Chlamydia antibodies by CF test. However, because Chlamydia CF antibody is not species specific, high CF titers also may result from C. pneumoniae and Chlamydia trachomatis infection. Acute- and convalescent-phase serum specimens should be obtained as soon as possible after onset of symptoms and greater than or equal to 2 weeks after onset of symptoms, respectively. Because treatment with tetracycline may delay or diminish the antibody response, a third serum sample may help confirm the diagnosis. All sera should be tested simultaneously at the same laboratory. If indicated by epidemiologic and clinical history, MIF assays can be used to distinguish C. psittaci infection from infection with other chlamydial species. Information about laboratory testing is often available at state laboratories. In humans, the infective agent can be isolated from sputum, pleural fluid, or clotted blood during acute illness before treatment with antibiotic. Treatment Tetracyclines are the drugs of choice for treating psittacosis in humans; most persons respond to oral therapy (100 mg of doxycycline administered twice a day or 500 mg of tetracycline hydrochloride administered four times a day). For severely ill patients, tetracycline hydrochloride may be administered intravenously at a dosage of 10-15 mg/kg of body weight/day. Remission of symptoms usually is evident within 48-72 hours. However, relapse may occur, and treatment must continue for at least 10-14 days after fever abates. Although its in-vivo efficacy has not been determined, erythromycin is probably the best alternative agent for persons for whom tetracycline is contraindicated (e.g., children aged less than 9 years and pregnant women). Reinfection can occur. Person-to-person transmission occurs only rarely; therefore, patient isolation and prophylaxis of contacts are not indicated. Responsibilities of Physicians Most states require physicians to report cases of psittacosis in humans to the appropriate health authorities. Timely diagnosis and reporting may aid in identifying the source of the infection and in controlling the spread of disease. Because single-serum titers are both insensitive and nonspecific for diagnosis of psittacosis, confirmation with paired acute- and convalescent-phase sera is recommended. Birds that are suspected sources of human infection should be referred to veterinarians for evaluation and treatment. Local and state authorities may conduct epidemiologic investigations and institute additional disease-control measures. Epidemiologic Investigations Epidemiologic investigations may be necessary to assist in controlling the transmission of C. psittaci in birds and humans. An epidemiologic investigation should be initiated if: a) a bird that has confirmed AC was procured from a pet store, breeder, or dealer within 60 days of the onset of its signs or b) a bird has come in contact with a human who has confirmed psittacosis. Humans or birds infected with or suspected of being infected with C. psittaci should be investigated at the discretion of the appropriate local or state public or animal health authorities. Investigations involving recently purchased birds should include a visit to the site where the infected bird is located and identification of the location where the bird was originally procured (e.g., pet shops, dealers, breeders, and quarantine stations). In conducting investigations, important considerations may include documenting the number and type(s) of birds involved, the health status of potentially affected persons and birds, locations of facilities where birds were housed, relevant ventilation-related factors, the treatment protocol, and the source of medicated feed, if such treatment is initiated. To facilitate identification of multistate outbreaks of C. psittaci infection, local and state authorities should report suspected outbreaks to the Childhood and Respiratory Diseases Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, CDC; telephone (404) 639-2215. References
Bibliography Fudge AM. Avian chlamydiosis. In: Rosskopf WJ, Woerpel RW, eds. Diseases of cage and aviary birds. Baltimore: Williams & Wilkins, 1996:572-85. Gelach H. Chlamydia. In: Ritchie BW, Harrison GJ, Harrison LR, eds. Avian medicine, principles and applications. Lake Worth, FL: Wingers Publishing, 1994:984-96. Reports from the symposium on avian chlamydiosis. J Am Vet Med Assoc 1989;195:1501-76. Schlossberg D. Chlamydia psittaci (psittacosis). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious disease, 4th ed. New York: Churchill Livingstone, 1995:1693-6. Schaffner W. Birds of a feather -- do they flock together? Infect Control Hosp Epidemiol 1997;18:162-4. Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices. **Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.Page converted: 09/19/98 |
|||||||||
This page last reviewed 5/2/01
|